Continuous versus intermittent treatment strategies during primary HIV-1 infection: The randomized ANRS INTERPRIM Trial

AIDS

Volumn 26, Issue 15, 2012, Pages 1895-1905

  Goujard, Cécile ^a,b   Emilie, Dominique ^c   Roussillon, Caroline ^d,e   Godot, Véronique ^c   Rouzioux, Christine ^f   Venet, Alain ^d   Colin, Céline ^d,e   Pialoux, Gilles ^g   Girard, Pierre Marie ^h   Boilet, Valérie ^d,e   Chaix, Marie Laure ^f   Galanaud, Pierre ^c   Chene, Geneviève ^d,e,i  

^a BICÊTRE HOSPITAL   (France)

^b CENTRE FOR RESEARCH IN EPIDEMIOLOGY AND POPULATION HEALTH   (France)

^c Universite Paris Sud   (France)

^d INSERM   (France)

^e UNIVERSITÉ DE BORDEAUX   (France)

^f HÔPITAL NECKER ENFANTS MALADES   (France)

^g HÔPITAL TENON   (France)

^h HÔPITAL SAINT ANTOINE   (France)

ⁱ BORDEAUX UNIVERSITY HOSPITAL   (France)

Author keywords

antiretroviral treatment; HIV 1; interferon; primary infection; treatment interruption

Indexed keywords

ANTIGEN P24; ANTIRETROVIRUS AGENT; CD4 ANTIGEN; CD8 ANTIGEN; GAMMA INTERFERON; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PEGINTERFERON ALPHA2B; RITONAVIR; VIRUS DNA; VIRUS RNA;

ABDOMINAL PAIN; ADULT; ANEMIA; ARTICLE; ASTHENIA; CD4 CD8 RATIO; CD4+ T LYMPHOCYTE; COMPARATIVE STUDY; CONTROLLED STUDY; DEPRESSION; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; FEMALE; FLU LIKE SYNDROME; FOLLOW UP; GASTROINTESTINAL TOXICITY; GENERALIZED EPILEPSY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MULTICENTER STUDY; NAUSEA; NEUROTOXICITY; NEUTROPENIA; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REBOUND; SIDE EFFECT; SUICIDE ATTEMPT; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; VIRUS INHIBITION; VIRUS LOAD; VOMITING;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; ANTI-HIV AGENTS; CD4-CD8 RATIO; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; DNA, VIRAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HIV-1; HUMANS; INTERFERON-ALPHA; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84866735012     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32835844d9     Document Type: Article

References (41)

1. Lyles RH, Munoz A, Yamashita TE, Bazmi H, Detels R, Rinaldo CR, et al. Natural history of human immunodeficiency virus type 1 viremia after seroconversion and proximal to AIDS in a large cohort of homosexual men. Multicenter AIDS Cohort Study. J Infect Dis 2000; 181:872-880. (Pubitemid 30194468)
2. Sterling TR, Vlahov D, Astemborski J, Hoover DR, Margolick JB, Quinn TC. Initial plasma HIV-1 RNA levels and progression to AIDS in women and men. N Engl J Med 2001; 344:720-725. (Pubitemid 32204989)
3. Rouzioux C, Hubert J-B, Burgard M, Deveau C, Goujard C, Bary M, et al. Early levels of HIV-1 DNA in peripheral blood mononuclear cells are predictive of disease progression independently of HIV-1 RNA levels and CD4RT cell counts. J Infect Dis 2005; 192:46-55. (Pubitemid 40863856)
4. Rodríguez B, Sethi AK, Cheruvu VK, Mackay W, Bosch RJ, Kitahata M, et al. Predictive value of plasma HIV-RNA level on rate of CD4 T-cell decline in untreated HIV infection. JAMA 2006; 296:1498-1506. (Pubitemid 44465514)
5. Goujard C, Bonarek M,Meyer L, Bonnet F, Chaix M-L, Deveau C, et al. CD4 cell count and HIV-DNA level are independent predictors of disease progression after primary HIV type 1 infection in untreated patients. Clin Infect Dis 2006; 42:709-715. (Pubitemid 43271388)
6. Ganesan A, Chattopadhyay PK, Brodie TM, Qin J, Gu W, Mascola JR, Michael NL, et al. Immunologic and virologic events in early HIV infection predict subsequent rate of progression. J Infect Dis 2010; 201:272-284.
7. Bell SK, Little SJ, Rosenberg ES. Clinical management of acute HIV infection: best practice remains unknown. J Infect Dis 2010; 202 (Suppl 2):S278-S288.
8. D'Souza MP, Axten KL, Hecht FM, Altfeld M. Acute HIV-1 Infection: what's new? where are we going?. J Infect Dis 2010; 202 (Suppl 2):S267-S269.
9. Cohen MS, Shaw GM, McMichael AJ, Haynes BF. Acute HIV-1 Infection. N Engl J Med 2011; 364:1943-1954.
10. Hogan CM, Degruttola V, Sun X, Fiscus SA, Del Rio C, Hare CB, et al. Effect of immediate versus deferred antiretroviral therapy on virologic set point in recently HIV-1-infected individuals. J Infect Dis 2012; 205:87-96.
11. Fidler S, SPARTAC Trial Investigator. The effect of short-course antiretroviral therapy in primary HIV infection: final results from an international randomised controlled trial. Abstract WELBX06. 6th IAS Conference on pathogenesis, treatment and prevention. Rome, Italy, 17-20 July 2011.
12. Hoen B, Fournier I, Lacabaratz C, Burgard M, Charreau I, Chaix ML, et al. Structured treatment interruptions in primary HIV-1 infection: the ANRS 100 PRIMSTOP trial. J Acquir Immune Defic Syndr 2005; 40:307-316. (Pubitemid 41533071)
13. Volberding P, Demeter L, Bosch RJ, Aga E, Pettinelli C, Hirsch M, et al. Antiretroviral therapy in acute and recent HIV infection: a prospective multicenter stratified trial of intentionally interrupted treatment. AIDS 2009; 23:1987-1995.
14. Stetson DB, Medzhitov R. Antiviral defence: interferons and beyond. J Exp Med 2006; 203:1837-1841.
15. Santini SM, Lapenta C, Logozzi M, Parlato S, Spada M, Di Pucchio T, et al. Type I interferon as a powerful adjuvant for monocyte-derived dendritic cell development and activity in vitro and in Hu-PBL-SCID mice. J Exp Med 2000; 191:1777-1788. (Pubitemid 30331574)
16. Garcia-Sastre A, Biron C. Type 1 interferons and the virushost relationship: a lesson in detente. Science 2006; 312:879-882. (Pubitemid 43727313)
17. Asmuth DM, Murphy RL, Rosenkranz SL, Lertora JJ, Kottilil S, Cramer Y, et al. Safety, tolerability, and mechanisms of antiretroviral activity of pegylated interferon Alfa-2a in HIV-1-monoinfected participants: a phase II clinical trial. J Infect Dis 2010; 201:1686-1696.
18. Avettand-Fenoel V, Boufassa F, Galimand J, Meyer L, Rouzioux C. HIV-1 DNA for the measurement of the HIV reservoir is predictive of disease progression in seroconverters whatever the mode of result expression is. J Clin Virol 2008; 42:399-404.
19. Lafeuillade A, Poggi C, Hittinger G, Counillon E, Emilie D. Predictors of plasma human immunodeficiency virus type 1 RNA control after discontinuation of highly active antiretroviral therapy initiated at acute infection combined with structured treatment interruptions and immune-based therapies. J Infect Dis 2003; 188:1426-1432. (Pubitemid 37523927)
20. Hamdi H, Mariette X, Godot V, Weldingh K, Hamid AM, Prejean MV, et al. Inhibition of antituberculosis T-lymphocyte function with tumour necrosis factor antagonists. Arthritis Res Ther 2006; 8:R114-R119.
21. Lacabaratz-Porret C, Urrutia A, Doisne J-M, Goujard C, Deveau C, Dalod M, et al. Impact of antiretroviral therapy and changes in virus load on human immunodeficiency virus (HIV)-specific T cell responses in primary HIV infection. J Infect Dis 2003; 187:748-757. (Pubitemid 36286935)
22. Markowitz M, Jin X, Hurley A, Simon V, Ramratnam B, Louie M, et al. Discontinuation of antiretroviral therapy commenced early during the course of human immunodeficiency virus type 1 infection, with or without adjunctive vaccination. J Infect Dis 2002; 186:634-643. (Pubitemid 34925535)
23. Hoen B, Cooper DA, Lampe FC, Perrin L, Clumeck N, Phillips AN, et al. Predictors of virological outcome and safety in primary HIV type 1-infected patients initiating quadruple antiretroviral therapy: QUEST GW PROB3005. Clin Infect Dis 2007; 45:381-390. (Pubitemid 47101038)
24. Goujard C, Marcellin F, Hendel-Chavez H, Burgard M, Meiffre ́dy V, Venet A, et al. Interruption of antiretroviral therapy initiated during primary HIV-1 infection: impact of a therapeutic vaccination strategy combined with interleukin (IL)-2 compared with IL-2 alone in the ANRS 095 Randomized Study. AIDS Res Hum Retroviruses 2007; 23:1105-1113. (Pubitemid 47571934)
25. Lampe FC, Porter K, Kaldor J, Law M, Kinloch-de Loes S, Phillips AN. Effect of transient antiretroviral treatment during acute HIV infection: comparison of the Quest trial results with CASCADE natural history study. Antivir Ther 2007; 12:189-193. (Pubitemid 46569904)
26. Lewin SR, Murray JM, Solomon A, Wightman F, Cameron PU, Purcell DJ, et al. Virologic determinants of success after structured treatment interruptions of antiretrovirals in acute HIV-1 infection. J Acquir Immune Defic Syndr 2008; 47:140-147. (Pubitemid 351172180)
27. Kaufmann DE, Lichterfeld M, Altfeld M, Addo MM, Johnston MN, Lee PK, et al. Limited durability of viral control following treated acute HIV infection. PLoS Med 2004; 1:e36.
28. Desquilbet L, Goujard C, Rouzioux C, Sinet M, Deveau C, Chaix M-L, et al.Does transientHAART during primaryHIV-1 infection lower the virological set-point? AIDS 2004; 18:2361-2369. (Pubitemid 40065903)
29. Kinloch-de Loes S, Hoen B, Smith DE, Autran B, Lampe FC, Phillips AN, et al. Impact of therapeutic immunization on HIV-1 viremia after discontinuation of antiretroviral therapy initiated during acute infection. J Infect Dis 2005; 192:607-617. (Pubitemid 41099309)
30. Hecht FM, Wang L, Collier A, Little S, Markowitz M, Margolick J, et al. A multicenter observational study of the potential benefits of initiating combination antiretroviral therapy during acute HIV infection. J Infect Dis 2006; 194:725-733. (Pubitemid 44344118)
31. Streeck H, Jessen H, Alter G, Teigen N, Waring MT, Jessen A, et al. Immunological and virological impact of highly active antiretroviral therapy initiated during acute HIV-1 infection. J Infect Dis 2006; 194:734-739. (Pubitemid 44344119)
32. Steingrover R, Garcia EF, van Valkengoed IGM, Bekker V, Bezemer D, Kroon FP, et al. Transient lowering of the viral set point after temporary antiretroviral therapy of primary HIV type 1 infection. AIDS Res Hum Retroviruses 2010; 26:379-387.
33. Seng R, Goujard C, Desquilbet L, Sinet M, Rouzioux C, Deveau C, et al. Rapid CD4R cell decrease after transient cART initiated during primary HIV infection (ANRS PRIMO and SEROCO cohorts). J Acquir Immune Defic Syndr 2008; 49:251-258.
34. Goujard C, Girault I, Rouzioux C, Lécuroux C, Deveau C, Chaix ML, et al. HIV-1 control after interruption of antiretroviral treatment initiated during primary infection: importance of early patient characteristics and impact of therapy. Antiviral Ther 2012 [E-pub ahead of print] doi:10:3851/IMP2273.
35. Hocqueloux L, Prazuck T, Avettand-Fenoel V, Lafeuillade A, Cardon B, Viard J-P, et al. Long-Term immunovirologic control following antiretroviral therapy interruption in patients treated at the time of primary HIV-1 infection. AIDS 2010; 24:1598-1601.
36. Gay CL, Mayo AJ, Mfalila CK, Chu H, Barry AC, Kuruc JD, et al. Efficacy of NNRTI-based antiretroviral therapy initiated during acute HIV infection. AIDS 2011; 25:941-949.
37. Goujard C, Chaix ML, Lambotte O, Deveau C, Sinet M, Guergnon J, et al. Spontaneous control of viral replication during primary HIV infection: when is 'HIV controller' status established? Clin Infect Dis 2009;49:982-986.
38. Von Wyl V, Gianella S, Fischer M, Niederoest B, Kuster H, Battegay M, et al. Early antiretroviral therapy during primary HIV-1 infection results in a transient reduction of the viral setpoint upon treatment interruption. PLos One 2011; 6:e27463.
39. Emilie D, Burgard M, Lascoux-Combe C, Laughlin M, Krzysiek R, Pignon C, et al. Early control of HIV replication in primary HIV-1 infection treated with antiretroviral drugs and pegylated IFN alpha: results from the Primoferon A (ANRS 086) Study. AIDS 2001; 15:1435-1437. (Pubitemid 32662296)
40. Adalid-Peralta L, Godot V, Colin C, Krzysiek R, Tran T, Poignard P, et al. Stimulation of the primary anti-HIV antibody response by IFN-Alpha in patients with acute HIV-1 infection. J Leukoc Biol 2008; 83:1060-1067. (Pubitemid 351959887)
41. Boué F, Reynes J, Rouzioux C, Emilie D, Souala F, Tubiana R, et al. Alpha interferon administration during structured interruptions of combination antiretroviral therapy in patients with chronic HIV-1 infection: INTERVAC ANRS 105 trial. AIDS 2011; 25:115-118.